Journal of International Oncology››2014,Vol. 41››Issue (2): 144-147.doi:10.3760/cma.j.issn.1673-422X.2014.02.019
Previous ArticlesNext Articles
Kong Mian, Li Baojiang, Wang Junye, Cao Kaiyuan, Lin Yu, Dai Shuqin
Received:
2013-06-04Revised:
2013-11-21Online:
2014-02-08Published:
2014-01-26Contact:
Dai Shuqin E-mail:daishq@sysucc.org.cnKong Mian, Li Baojiang, Wang Junye, Cao Kaiyuan, Lin Yu, Dai Shuqin. Screen peptides specifically bonding to MDA-MB-231 breast cancer cells[J]. Journal of International Oncology, 2014, 41(2): 144-147.
[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30. [2] Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985, 228(4705): 1315-1317. [3] Laine AL, Adriaenssens E, Vessieres A, et al. The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer[J]. Biomaterials, 2013, 34(28): 6949-6956. [4] Heo CK, Hwang HM, Ruem A, et al. Identification of a mimotope for circulating anticytokeratin 8/18 antibody and its usage for the diagnosis of breast cancer[J]. Int J Oncol, 2013, 42(1): 65-74. [5] Kong M, Wang JY, Li BJ. Application of phage display technology in targeted therapy of breast cancer[J]. ChineseGerman J Clin Oncol, 2013, 12(5): 246-248. [6] Lin J, Huo R, Wang L, et al. A novel antiCyr61 antibody inhibits breast cancer growth and metastasis in vivo[J]. Cancer Immunol Immunother, 2012, 61(5): 677-687. [7] NewtonNorthup JR, Dickerson MT, Ma L, et al. Inhibition of metastatic tumor formation in vivo by a bacteriophage displayderived galectin3 targeting peptide[J]. Clin Exp Metastasis, 2013, 30(2): 119-132. |
[1] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[2] | Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[3] | Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238. |
[4] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[5] | Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer: present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58. |
[6] | Wang Jing, Xu Wenting.Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526. |
[7] | Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531. |
[8] | Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456. |
[9] | Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462. |
[10] | Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356. |
[11] | Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367. |
[12] | Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240. |
[13] | Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149. |
[14] | Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96. |
[15] | Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||